These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3191493)

  • 1. Deferoxamine inhibition of human neuroblastoma viability and proliferation.
    Becton DL; Bryles P
    Cancer Res; 1988 Dec; 48(24 Pt 1):7189-92. PubMed ID: 3191493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines.
    Becton DL; Roberts B
    Cancer Res; 1989 Sep; 49(17):4809-12. PubMed ID: 2758414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
    Brodie C; Siriwardana G; Lucas J; Schleicher R; Terada N; Szepesi A; Gelfand E; Seligman P
    Cancer Res; 1993 Sep; 53(17):3968-75. PubMed ID: 8358725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferoxamine in children with recurrent neuroblastoma.
    Blatt J
    Anticancer Res; 1994; 14(5B):2109-12. PubMed ID: 7840508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
    Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
    Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
    Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines.
    Selig RA; Madafiglio J; Haber M; Norris MD; White L; Stewart BW
    Anticancer Res; 1993; 13(3):721-5. PubMed ID: 8317903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
    Brard L; Granai CO; Swamy N
    Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelator-induced growth arrest and cytochrome c-dependent apoptosis in immortalized and malignant oral keratinocytes.
    Lee SK; Lee JJ; Lee HJ; Lee J; Jeon BH; Jun CD; Lee SK; Kim EC
    J Oral Pathol Med; 2006 Apr; 35(4):218-26. PubMed ID: 16519769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
    Yang DC; Jiang XP; Elliott RL; Head JF
    Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of dopamine transporter by iron chelation in vitro is mediated by altered trafficking, not synthesis.
    Wiesinger JA; Buwen JP; Cifelli CJ; Unger EL; Jones BC; Beard JL
    J Neurochem; 2007 Jan; 100(1):167-79. PubMed ID: 17227437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineuroblastoma activity of desferoxamine in human cell lines.
    Blatt J; Stitely S
    Cancer Res; 1987 Apr; 47(7):1749-50. PubMed ID: 3815370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different exposures to desferrioxamine on neuroblastoma cell lines.
    Valle P; Timeus F; Piglione M; Rosso P; di Montezemolo LC; Crescenzio N; Marranca D; Ramenghi U
    Pediatr Hematol Oncol; 1995; 12(5):439-46. PubMed ID: 8519628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activities of four chelating agents against human neuroblastoma cells.
    Shen L; Zhao HY; Du J; Wang F
    In Vivo; 2005; 19(1):233-6. PubMed ID: 15796180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
    Fan L; Iyer J; Zhu S; Frick KK; Wada RK; Eskenazi AE; Berg PE; Ikegaki N; Kennett RH; Frantz CN
    Cancer Res; 2001 Feb; 61(3):1073-9. PubMed ID: 11221835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
    Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
    Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of deferoxamine against Porphyromonas gingivalis.
    Moon JH; Herr Y; Kim SW; Lee JY
    FEMS Microbiol Lett; 2011 Oct; 323(1):61-7. PubMed ID: 22092680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.